/
Respiratory
Obstructive Sleep Apnea
39
Pipeline Programs↗
99
Active Trials↗
46
Companies Involved↗
Obstructive Sleep Apnea is a moderately active landscape with 39 programs across 46 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Innovent Biologics (Suzhou) Co. Ltd., Amgen. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 11
Phase 24
Phase 311
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
28 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 85% of 39 pipeline programs.
Analysis
Trial Status
246
clinical trials
Completed109 · 44%
Recruiting51 · 21%
Not yet recruiting34 · 14%
Withdrawn13 · 5%
Unknown status12 · 5%
Terminated11 · 4%
Other16 · 7%
Clinical Trials
Trial Activity
246 trials
Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study
Recruiting·—·Approved·NCT07679282·2,400 enrolled
Myofunctional Therapy for Obstructive Sleep Apnea in U.S. Service Members With and Without Traumatic Brain Injury
Recruiting·UUniformed Services University of the Health Sciences·Preclinical·NCT07301710·60 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)